H1 Approvals Seen For Russian, Novavax COVID-19 Vaccines In India
J&J, Pfizer Yet To Begin Local Trials
Multiple COVID-19 vaccines, including from RDIF and Novavax, could get accelerated approvals in India in the first half of calendar 2021, expanding the range at the country’s disposal. J&J's vaccine is expected to follow although it still hasn’t begun local trials, while Pfizer has temporarily withdrawn an application.
You may also be interested in...
BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.
In an unusual move prompted by an enormous second wave of infections, India is accelerating approvals for COVID-19 vaccines granted emergency use authorizations by other selected regulators or on the WHO’s emergency use list without a local bridging study. While this seems a prelude to permitting private sales, where will the supplies come from?
Concerns that new or future mutations of the novel coronavirus may reduce the protection offered by existing COVID-19 vaccines have prompted the European Medicines Agency to develop guidance to help vaccine manufacturers who are planning to alter to their products.